Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Alterations of Immunologic Mediators During Severe Sepsis (LAVISS_01)

This study has been terminated.
(anticipated number of patients could not be reached)
University of Halle Medical Faculty
Information provided by (Responsible Party):
Armin Sablotzki, MD, Klinikum St. Georg gGmbH Identifier:
First received: June 7, 2007
Last updated: February 7, 2017
Last verified: February 2017
Severe sepsis induces significant changes in expression of insulin- and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.

Severe Sepsis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Alterations of Immunologic Mediators During Severe Sepsis

Resource links provided by NLM:

Further study details as provided by Klinikum St. Georg gGmbH:

Primary Outcome Measures:
  • severity of sepsis [ Time Frame: 96 hours after diagnosis of sepsis ]

Biospecimen Retention:   Samples Without DNA
Whole Blood Samples, Plasma Samples

Enrollment: 20
Study Start Date: June 2006
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Detailed Description:
In patients at early stage of severe sepsis, we investigate the expression of pro- and anti-inflammatory cytokines, chemokines, adhesion-molecules, toll-like receptors, insulin-receptors, markers of apoptosis und of t- and b-cell-activation on a mRNA level.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with early stage of severe sepsis and septic shock

Inclusion Criteria:

  • age >= 18 y
  • agreement with study procedures
  • 3 of 4 SIRS-criteria
  • proven or highly suspected infection
  • 2 or more sepsis-induced organ failures
  • start of first sepsis-induced organ failure within the last 36 hours

Exclusion Criteria:

  • non-agreement with study procedures
  • signs of severe sepsis with organ failure > 36 hours
  • chronic immuno-compromising diseases
  • chronic therapy with anti-inflammatory drugs
  • non-curable cancer
  • chronic renal failure with hemodialysis
  • pregnancy or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00484146

Klinikum St. Georg gGmbH, Interdisciplinary Intensive Care Unit
Leipzig, Sachsen, Germany, 04129
Sponsors and Collaborators
Klinikum St. Georg gGmbH
University of Halle Medical Faculty
Principal Investigator: Armin R Sablotzki, MD Klinikum St. Georg gGmbH
  More Information

Responsible Party: Armin Sablotzki, MD, Prof. Dr. med., Klinikum St. Georg gGmbH Identifier: NCT00484146     History of Changes
Other Study ID Numbers: ISRCTN34508816
Study First Received: June 7, 2007
Last Updated: February 7, 2017

Keywords provided by Klinikum St. Georg gGmbH:
Early Stage
Immune System

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes processed this record on April 27, 2017